Acetoacetic Acid Sodium Salt: Evidence and Scope
Acetoacetic acid sodium salt, also known as sodium 3-oxobutanoate, is described by APExBIO as a sodium-form ketone body and a non-esterified fatty acid metabolite associated with energy metabolism. The supplier identifies the compound by CAS number 623-58-5, reports a molecular weight of 124.07, and lists a stated purity of 98%, supported by a Certificate of Analysis, mass spectrometry, and nuclear magnetic resonance data. These details establish the product’s documented catalog identity and quality claims; they do not, by themselves, demonstrate a biological effect or validate a disease model. The central product information is available from the Acetoacetic acid sodium salt product page.
Documented identity and scientific context
The product description places sodium 3-oxobutanoate within ketone-body metabolism and links it to fatty acid catabolism in the liver. It further states that the sodium salt rapidly converts to acetoacetic acid in the body. Accordingly, the product is presented as a chemically defined source of an acetoacetate-related species rather than as an enzyme, receptor ligand, or disease-specific therapeutic agent.
This distinction matters for energy metabolism research. A catalog designation can identify the molecular entity supplied, while the biological meaning of an acetoacetate measurement depends on the model, specimen, analytical method, and physiological context. None of those study-level details are supplied here. The available information therefore supports a metabolic-context overview, not a conclusion that the product has been validated for a particular cellular, animal, or clinical application.
Documented mechanism and measurement meaning
According to the APExBIO description, acetoacetic acid is a ketone body involved in energy metabolism and related to fatty acid catabolism. The supplier also characterizes sodium acetoacetate as converting rapidly to acetoacetic acid in the body. Taken together, the documented mechanism is a broad metabolic association: the compound is positioned within a pathway in which fatty-acid-derived ketone bodies participate in energy handling.
The measurement interpretation is narrower than the pathway label. An elevated ketone-body concentration can be a downstream observation associated with metabolic imbalance, but that observation does not by itself establish the upstream cause, the direction of metabolic flux, or a causal role for acetoacetate in tissue injury. The product page specifically connects elevated ketone bodies with diabetes-related imbalance and states that they can lead to diabetic ketoacidosis. Because no identity-matched study, quantitative dataset, or mechanistic experiment is available here, that statement should be treated as supplier-level contextual information rather than as evidence of an effect size or causal relationship for this product.
For a diabetic ketoacidosis study, this distinction is particularly important. Acetoacetate may function conceptually as a ketone-body readout, while the presence of the readout alone cannot identify whether it reflects altered production, altered utilization, broader metabolic stress, or another unreported factor. The supplied information does not distinguish among those possibilities and does not report clinical thresholds, patient outcomes, or diagnostic performance.
Interpretation of the reported product properties
APExBIO reports water solubility of at least 23.7 mg/mL, solubility in DMSO of at least 5.9 mg/mL with ultrasonic assistance, and insolubility in ethanol. These are product-level physicochemical descriptors. They may help define the material’s formulation profile, but they do not establish bioavailability, stability in a biological matrix, cellular uptake, or assay performance. The stated storage and cold-shipping information likewise concerns product integrity and logistics, not metabolic mechanism.
The reported 98% purity and supporting mass-spectrometric and nuclear-magnetic-resonance documentation provide provenance for the commercial material as characterized by the supplier. They should not be conflated with biological validation. In particular, the information does not report impurity effects, stability of solutions over time, conversion kinetics between the sodium salt and acetoacetic acid, or concordance between the product and endogenous acetoacetate measurements.
| Claim | Reported basis | Interpretive boundary |
|---|---|---|
| Identity | Sodium 3-oxobutanoate; CAS 623-58-5; molecular weight 124.07 | Supports catalog identification, not biological performance |
| Metabolic role | Described as a ketone body associated with fatty acid catabolism and energy metabolism | Provides pathway context, not evidence of a demonstrated causal mechanism in a defined model |
| Diabetes relevance | Elevated ketone bodies are described as indicators of metabolic imbalance and as associated with ketoacidosis | Does not supply diagnostic accuracy, clinical outcomes, or product-specific effect estimates |
| Quality and physical properties | 98% stated purity, analytical documentation, and reported solubility characteristics | Characterizes the commercial material; does not validate assay suitability or physiological exposure |
Evidence availability and applicability boundaries
No identity-matched research paper is available in the evidence accompanying this product. Consequently, there are no supported sample sizes, comparators, effect sizes, uncertainty estimates, biological models, or study-specific readouts to summarize. The absence of such data is not evidence that the compound lacks activity; it means that activity and performance have not been established by the supplied research record.
A related contextual article, “Acetoacetic Acid Sodium Salt: Evidence and Scope”, similarly presents the catalog identity and explicitly distinguishes those product claims from the absence of an identity-matched study. Because it provides no primary experimental dataset in the supplied material, it is best treated as secondary context rather than independent validation.
Direct comparisons are also unavailable. The evidence does not compare sodium 3-oxobutanoate with acetoacetic acid in another formulation, other ketone bodies, esterified compounds, or alternative commercial sources. Nor does it establish that the reported water or DMSO solubility predicts performance in a biological matrix. These boundaries prevent extrapolation from product characterization to claims about pathway flux, cellular effects, diabetes progression, or treatment.
Factual synthesis
The documented record identifies Acetoacetic acid sodium salt as sodium 3-oxobutanoate, a ketone-body-related metabolite positioned by APExBIO within energy metabolism and the fatty acid catabolism pathway. The supplier reports its identity, stated purity, analytical documentation, and selected physicochemical properties, and describes conversion to acetoacetic acid in the body. Those claims support a conceptual role in metabolic measurement and disease-context discussions, including diabetes metabolic imbalance.
They do not constitute evidence of a validated biological mechanism, product-specific performance, clinical utility, or therapeutic effect. For researchers, the most defensible interpretation is therefore a source-attributed product and mechanism overview with clear separation between chemical identity, pathway context, and demonstrated biological outcome.